Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

sections

    EMA

    Oxervate gets EMA approval for rare degenerative eye disease

    The European Medicines Agency (EMA), which evaluates medicinal products for use in Europe, has recommended Oxervate (marketed by Dompé) for marketing authorisation for the treatment of moderate or severe neurotrophic keratitis.

    The eye disease results from damage to the trigeminal nerve and subsequent progressive degeneration of the cornea. In severe cases it can lead to blindness.

    There are currently no specific pharmacological treatments for the eye disease, which is often managed with artificial tears and antibiotics, as well as surgery, in some cases.

    Oxervate, whose active ingredient is cenegermin, is a recombinant form of human nerve growth factor, delivered via eye drops, and is intended to recover an adequate nerve response to preserve and heal the cornea.

    The EMA recommendation was based on data from two phase II clinical trials involving 204 patients with moderate and severe disease. In both studies, more Oxervate-treated patients achieved complete corneal healing after eight weeks compared with placebo-treated patients.

    The most common adverse reactions included eye and eyelid pain, eye inflammation, increased tear production and a foreign-body sensation in the eye.

    Oxervate was reviewed under the EMA’s accelerated assessment programme, intended to increase access to treatments that address unmet medical needs, after receiving orphan designation in 2015. Neurotrophic keratitis is thought to affect between 1 and 5 people out of every 10,000.

    Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202842

    Have your say

    For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

    Recommended from Pharmaceutical Press

    • Drugs and the Liver

      Drugs and the Liver

      Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

      £38.00Buy now
    • Introduction to Renal Therapeutics

      Introduction to Renal Therapeutics

      Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

      £38.00Buy now
    • Minor Illness or Major Disease

      Minor Illness or Major Disease

      This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

      £43.00Buy now
    • Pathology and Therapeutics for Pharmacists

      Pathology and Therapeutics for Pharmacists

      An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

      £54.00Buy now
    • Biological Therapeutics

      Biological Therapeutics

      An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

      £33.00Buy now

    Search an extensive range of the world’s most trusted resources

    Powered by MedicinesComplete
    • Print
    • Share
    • Comment
    • Save
    • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF
    grouped logos

    Site powered by Webvision